The Common Good is a guest speaker series hosted by the PCDC. We’re inviting thought leaders from across the fields of oncology, clinical trials, and international data sharing to talk about big ideas that can redefine how we think about improving human health. The more we learn from each other, the better we can all work toward the common good.
NEXT TALK
The Common Good series will be on a brief hiatus this winter.
We look forward to our next talk in spring 2023!
PAST TALKS
Bioethics and Relevant Considerations for Data Sharing
We apologize that video from this session is not available to share.
Karla Childers, Bioethics & Strategic Projects Leader at Johnson & Johnson and an industry expert in bioethics policy, data sharing, and data transparency, joins the Common Good for a brief overview of bioethics and a discussion on the ethical considerations of the sharing of health data. Presented on October 13, 2022.
Addressing Global Disparities in Childhood Cancer: Now Is the Time
Carlos Rodriguez-Galindo, MD, director of St. Jude Global and chair of the Department of Global Pediatric Medicine, reviews the current estimates of the global burden of childhood cancer and disparities in access to quality care, and discusses current initiatives to address them. Presented on July 21, 2022.
Harnessing Collaborative Frameworks Across Consortia as Paired with Emerging National Data-driven Infrastructure to Advance Clinical Translation for Children with Brain Tumors
The Common Good welcomes Adam Resnick, PhD, Director of the Center for Data Driven Discovery in Biomedicine at Children’s Hospital of Philadelphia and Principal Investigator of the Gabriella Miller Kids First Data Resource Center. Pediatric brain tumors are the leading cause of disease-related death in children. To address the unmet need for large-scale datasets that can inform new research and therapeutic development across the heterogeneous disease landscape of pediatric brain tumors, multi-institutional national/international consortia like the Children’s Brain Tumor Network have undertaken the centralized integration of samples and associated clinical/phenotypic patient data on behalf of a collaborative discovery research framework. Over the past five years, such efforts have further informed the development of the Gabriella Miller Kids First Data Resource, an NIH-supported, cloud-based platform focused on pediatric cross-disease analyses, as well as further contributed to NCI-sponsored data generation efforts supported by the Clinical Proteomic Tumor Analysis Consortium (CPTAC) and more recently the Childhood Cancer Data Initiative (CCDI). Together, these large-scale data and platform resources are newly poised to advance and inform an emerging pediatric data commons landscape on behalf of accelerated, collaborative discovery and translational clinical impact. Presented on April 19, 2022.
Putting Children First: New Models for Pediatric Oncology Drug Development
Sam Blackman, MD, PhD, co-founder and Chief Medical Officer of Day One Biopharmaceuticals, discusses how pediatric oncology drug development can change for the better. Dr. Blackman, who has led the early clinical development of more than 10 novel cancer therapeutics, describes the challenges that have limited the pace of development of new therapeutics for pediatric cancer, new business models that may be capable of changing this dynamic, and how the pediatric oncology ecosystem can work together to enable success. Presented on January 25, 2022.
2020 Vision: The Future of Clinical Trials Is Here. Are We?
Greg Simon, former President of the Biden Cancer Initiative, describes the recent progress made in patient-friendly clinical trials and the need to retain these changes to increase diversity and equity and to lessen the burden on patients wherever possible. Having leapt ten years ahead due to Covid, let’s not go back to 2019. Presented on October 27, 2021.
Be the first to know about future talks in this series by signing up for the PCDC email list!
The views and opinions expressed in Common Good talks are those of the speakers and do not necessarily reflect the official policy or position of the Pediatric Cancer Data Commons or the University of Chicago.